Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: a case report

Several small molecules, epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib and afatinib, have been demonstrated to significantly improve clinical outcomes in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC), but erlotinib ac...

Full description

Saved in:
Bibliographic Details
Published in:International medical case reports journal 2017-01, Vol.10, p.173-175
Main Authors: Gambale, Elisabetta, Carella, Consiglia, Amerio, Paolo, Buttitta, Fiamma, Patea, Rosa Lucia, Natoli, Clara, De Tursi, Michele
Format: Article
Language:English
Subjects:
Cancer therapies
Care and treatment
Case Report
Case reports
Chemotherapy
Chronic obstructive pulmonary disease
Clinical trials
Cytotoxicity
Development and progression
EGFR wild type
Epidermal growth factor
Erlotinb
Erlotinib
Family medical history
Gene amplification
Gene expression
Genetic aspects
Health aspects
Lung cancer
Lung cancer, Non-small cell
Medical imaging
Metastasis
Mutation
Patient outcomes
Patients
Quality of life
Skin
Squamous cell carcinoma
squamous NSCLC
Targeted cancer therapy
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Several small molecules, epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib and afatinib, have been demonstrated to significantly improve clinical outcomes in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC), but erlotinib activity in EGFR wild-type squamous carcinoma is still highly debated. Here, we describe a prolonged and unexpected clinical response to erlotinib in a male former heavy cigarette smoker with wild-type EGFR squamous-cell cancer.
ISSN:1179-142X
1179-142X
DOI:10.2147/IMCRJ.S134944